Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Portfolio Pulse from
Gilead Sciences announced positive interim results from its Phase 3 ASSURE study for Livdelzi (seladelpar), showing significant efficacy and safety in treating primary biliary cholangitis.
November 15, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' Livdelzi shows promising results in a Phase 3 study for primary biliary cholangitis, with 81% of patients achieving significant improvement.
The positive interim results from the Phase 3 study of Livdelzi indicate strong efficacy and safety, which could lead to increased investor confidence and potential future revenue from this treatment. This is likely to have a positive short-term impact on Gilead's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100